
    
      The study is double blind. However the active control vaccine Tritanrix™-HepB/Hiberix™ will
      be administered in a single-blind manner. Blood samples will be collected for immunogenicity
      analyses. GSK Biologicals' OPV vaccine will be administered concomitantly with the study
      vaccines at 2, 4 and 6 months of age according to local country regulation. The study will
      last approximately 5 months per subject
    
  